CRISPR Therapeutics AG (CRSP) Net Income (2015 - 2026)
CRISPR Therapeutics AG (CRSP) posted Net Income of -$122.9 million for Q1 2026, up 24.23% sequentially from -$162.2 million in Q4 2025, and up 9.6% YoY from -$112.2 million in Q1 2025.
CRISPR Therapeutics AG (CRSP) Net Income (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Net Income for 12 years, with the latest figure at -$122.9 million in Q1 2026.
- Quarterly Net Income rose 9.6% year-over-year to -$122.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$600.2 million (down 3391.11% YoY) and the FY2025 annual result came in at -$613.2 million, down 1728.93% from the prior year.
- Net Income advanced to -$122.9 million in Q1 2026 per CRSP's latest filing, from -$162.2 million in the prior quarter.
- Over five years, Net Income peaked at $366.6 million in Q4 2024 and troughed at -$208.5 million in Q2 2025.
- A 5-year average of -$88.4 million and a median of -$116.6 million in 2024 frame the typical range for Net Income.
- The sharpest annual moves came in 2024 and 2025: Net Income surged 310.09% in 2024, then tumbled 144.26% in 2025.
- Over 5 years, Net Income stood at -$110.6 million in 2022, then surged by 180.84% to $89.4 million in 2023, then soared by 310.09% to $366.6 million in 2024, then slumped by 144.26% to -$162.2 million in 2025, then rose by 24.23% to -$122.9 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$122.9 million, -$162.2 million, and -$106.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | -91.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -91.19 Mn |
| Mar 31, 2026 | -122.93 Mn |
| Dec 31, 2025 | -162.25 Mn |
| Sep 30, 2025 | -106.44 Mn |
| Jun 30, 2025 | -208.55 Mn |
| Mar 31, 2025 | -135.99 Mn |
| Dec 31, 2024 | 366.59 Mn |
| Sep 30, 2024 | -85.94 Mn |
| Jun 30, 2024 | -126.42 Mn |
| Mar 31, 2024 | -116.59 Mn |
| Dec 31, 2023 | 89.39 Mn |
| Sep 30, 2023 | -112.14 Mn |
| Jun 30, 2023 | -77.74 Mn |
| Mar 31, 2023 | -53.07 Mn |
| Dec 31, 2022 | -110.58 Mn |
| Sep 30, 2022 | -174.55 Mn |
| Jun 30, 2022 | -185.82 Mn |
| Mar 31, 2022 | -179.22 Mn |
| Dec 31, 2021 | -141.25 Mn |
| Sep 30, 2021 | -127.15 Mn |